Inspirata Accelerates Its Growth as a Leading Provider of AI/NLP Technology in Oncology Informatics

Digital Pathology Business to be Acquired by Long-Standing Partner Fujifilm; Unlocks Faster Deployment of Inspirata’s Resources for Growth in Strategic Focus Area

Inspirata  and FUJIFILM Corporation signed an asset purchase agreement for Fujifilm to acquire Inspirata’s Dynamyx digital pathology technology, employees and customers, building off the proven success of the established partnership between the companies in UK and Europe. This milestone allows the Digital Pathology business to flourish with a partner who has the breadth, depth and resources required to take the Dynamyx platform to the next stage of its growth and international expansion.

The strategic transaction also adds significant tailwinds behind Inspirata’s ongoing focus to become the leading provider of cloud-based, enterprise software as a service (SaaS) solutions for Oncology Informatics – its main strategic pillar of growth. Critical workflows in Oncology Informatics, such as clinical trial matching and cancer registry reporting and data abstraction, are ripe for disruption through the powerful and clinically optimized AI (artificial intelligence) and NLP (Natural Language Processing) technology that Inspirata has been developing over two decades.

Recommended AI: “Bitcoin Has No Intrinsic Value”. Then What Gives Bitcoin Value?

In 2023, Inspirata will focus its resources on further enhancing and developing its proprietary, purpose-built AI / NLP-enabled technology to support its growing customer base match larger and more diverse portions of their cancer patient populations to the most relative clinical trials in real time. The company will also continue its long-standing service of dozens of central state registries and hundreds of hospital cancer registries, who use Inspirata’s solutions to automate clinical data abstraction for cancer casefinding and reporting, representing one of the largest implementations of AI in the oncology informatics field.

“This landmark transaction is significant for both the future of digital pathology and the fulfillment of Inspirata’s growth strategy in cancer informatics. We strongly believe the Dynamyx solution and team responsible for building its advanced digital pathology workflow will find a great new home within Fujifilm’s Synapse Enterprise Imaging portfolio. We are confident our partners at Fujifilm will build on Dynamyx’s storied legacy and continue to be a driving force behind digitization in the healthcare imaging space,” says Satish Sanan, Chairman and CEO of Inspirata, Inc. “In the meantime, this allows Inspirata to align our resources with the broadening of our long-term strategic vision to expand the reach of our Trial Navigator and E-Path solutions among our existing and prospect customers at leading academic medical centers, NCI-designated cancer centers, and large healthcare networks.”

Recommended AI: Top 10 Countries and Cities by Number of CCTV Cameras

“Acquiring Inspirata’s digital pathology business allows Fujifilm to be an even stronger healthcare partner – bridging a technological gap between pathology, radiology and oncology to facilitate a more collaborative approach to care delivery across the enterprise,” says Teiichi Goto, President and CEO, representative director, FUJIFILM Corporation. “We’re thrilled to welcome Inspirata’s digital pathology experts to Fujifilm’s growing medical informatics business, along with their renowned global customer base, as together we work to drive the digitization and advancement of healthcare.”

Recommended AI: How is Artificial Intelligence (AI) Changing the Future of Architecture?

[To share your insights with us, please write to sghosh@martechseries.com]